Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
ELV — Elevance Health Inc.
NYSE
FULL STOCK PAGE →

Elevance Health Q1 2026 Earnings Call Summary

APR 22, 2026 2 MIN READ
REVENUE
$50.18B +0.9%
NET MARGIN
3.5% +2.4 PTS
EPS
$8.00 +223.9%
FREE CASH FLOW
$4.10B +2060.3%

1Key Financial Results and Metrics

Adjusted Diluted EPS: $12.58, exceeding expectations.

Operating Revenue: $49.5 billion, up 1.5% year-over-year.

Membership: 45.4 million members, an increase of nearly 200,000 from year-end.

Benefit Expense Ratio: 86.8%.

Operating Expense Ratio: 10.5%, improved by 20 basis points year-over-year.

Operating Cash Flow: $4.3 billion, with a full-year expectation of at least $5.5 billion.

Share Repurchases: 3.7 million shares for $1.1 billion at an average price of over $300 per share.

2Strategic Updates and Business Highlights

Leadership Realignment: Strengthened coordination between health benefits and Carelon to enhance execution.

AI Integration: Scaling AI across clinical and operational workflows, leading to improved member engagement and cost management.

Carelon Transformation: Integrated CareBridge and home care capabilities into a single risk-based solution, achieving a 20% reduction in hospital readmissions and over 10% savings on post-acute care.

Medicaid Initiatives: Early evidence of cost reductions in behavioral health and specialty pharmacy through targeted interventions.

Medicare Advantage: Improved performance driven by product repositioning, on track for at least a 2% operating margin in 2026.

Commercial Business: Maintained disciplined pricing, with strong employer interest and a robust pipeline for 2027.

3Forward Guidance and Outlook

Adjusted EPS Guidance: Raised to at least $26.75 for 2026, with expectations of at least 12% adjusted EPS growth in 2027.

Medicaid Membership: Anticipated high single-digit percentage decline due to eligibility reverifications, with expectations to finish towards the higher end of that range.

Carelon's Role: Expected to continue driving performance and long-term growth.

4Bad News, Challenges, or Points of Concern

CMS Risk Adjustment Data: Received a notice from CMS regarding historical data, leading to a $935 million accrual for potential exposure, although management remains confident in the integrity of current practices.

Medicaid Margin Pressure: Operating margin guidance for Medicaid remains at approximately -1.75%, with ongoing discussions for rate adjustments with states.

Membership Mix Concerns: Potential pressure on risk pools due to membership declines among lower-utilizing members, particularly in Medicaid.

5Notable Q&A Insights

Commercial Selling Season: Strong early interest from employers focused on affordability and experience, with a record pipeline for 2027.

Cost Trends: Cost trends are tracking in line with expectations, with proactive measures showing early benefits in managing claims.

AI and Automation: Investments in AI are aimed at reducing costs and improving member experience, with significant early adoption and positive results in operational efficiency.

Carelon's Performance: Continued investment in Carelon services is expected to enhance margins over time, despite current pressures from lower health plan membership.

Regulatory Environment: Ongoing federal actions on PBM transparency are seen as aligning with Elevance's business model, which focuses on integrated medical and pharmacy management. Overall, Elevance Health reported a strong start to 2026 with positive financial results and strategic initiatives aimed at improving efficiency and member engagement, while also navigating challenges in Medicaid and regulatory environments.

SOURCE: Q1 2026 EARNINGS CALL TRANSCRIPT